human IL-2, His-tag


Price excl. shipping costs excl. VAT. For more information, see our shipping policy

SKU: P2020-135 trenzyme

Need a quote for an individual request or for a bulk order?

Please contact us.


Interleukin-2 (IL-2) was first discovered as a T cell growth factor as it is a potent growth, survival, and differentiation factor for T lymphocytes, thereby playing a major role in activating immune responses. On the other hand, IL-2 is involved in immune suppression against self and other antigens by promoting the survival and function of regulatory T cells. It is put a lot of effort into designing various IL-2 constructs in order to enable the treatment of different types of diseases, especially cancer and autoimmune diseases.


  • Product Name: human Interleukin-2, His-tag
  • Catalog No.: P2020-135
  • RefSeq Links: NP_000577.2; NM_000586.3; pdb6lxw; UniProt: P60568
  • Synonyms: IL-2, T-cell growth factor (TCGF), lymphokine protein
Cellebrity Kolben Cell Cartoon trenzyme

Customer Testimonial

“We highly valued the fast and excellent communication and the high flexibility of the team! For any future project, we will preferably entrust in trenzyme’s protein production services.”

Dr. Thore Hettmann
Probiodrug AG, Halle/Saale, Germany

Sequence Information

  • Species: Homo sapiens
  • Tags: His-tag, N-terminal
  • Sequence without tags (AA 21-153)

Product Information

  • Expression Host: HEK293
  • Formulation: PBS; pH 7.4.
  • Format: Liquid, stored and shipped at -80° C
  • Purity: 95% as determined by SDS-PAGE

Background Information

Interleukin-2 (IL-2) is produced by naive T cells early after their activation by antigen-presenting cells (APCs) and stimulates survival, proliferation and differentiation of these antigen-activated T cells into effector and memory T cells acting as an autocrine or paracrine cytokine. Secreted IL-2 is a globular glycoprotein which exerts its function by binding to the IL-2 receptor (IL-2R). IL-2R is composed of three chains, IL-2R alpha (CD25), IL-2R beta (CD122) and the common gamma chain (CD132). Naive T cells and natural killer (NK) cells express low levels of IL-2R beta gamma complexes that can bind IL-2 with moderate affinity. Activation of T cells by antigens and costimulators leads to secretion of IL-2 and subsequently to expression of the IL-2R alpha chain enabling formation of high affinity receptor complexes, thereby promoting T cell responses. Strikingly, IL-2 not only promotes immune responses, but also controls T cells functions by promoting survival and function of regulatory T cells (Tregs) that play pivotal roles in suppressing immune responses against self and other antigens. In contrast to naive T cells, Tregs constitutively express high affinity trimeric IL-2R complexes and thus, low IL-2 concentrations are sufficient to initiate signaling. Due to its immunostimulatory effects, administration of high-dose IL-2 was approved as immunotherapy for the treatment of metastatic renal cell carcinoma and metastatic melanoma. However, efficacy in cancer treatment was limited because of severe adverse side effects such as the vascular leak syndrome. To improve efficacy, several combination therapies are being developed including antigen-specific vaccination, adoptive cell transfer and blockade of immune checkpoint inhibitory molecules. Furthermore, IL-2 is being tested as therapeutic agent for the control of graft-versus-host disease, autoimmune inflammation, and graft rejection by promoting the immunosuppressive functions of Tregs. In cell culture, recombinant IL-2 is commonly used to induce proliferation and differentiation of T cells, NK cells, as well as B cells.


SDS-PAGE/Coll. Coomassie

Histogram of marked lane in gel picture

SDS-Page human IL-2, His-tag
Histogram human IL-2, His-tag
Cellular response to human IL-2, His-tag

Get in contact with us

By submitting this form, I consent to trenzyme GmbH receiving and processing my data in order to process my inquiry. My consent is voluntary and I may revoke this consent at any time without providing any reasons, e.g. by sending an email to privacy(at) with effect for the future. Further notices on data processing can be found in our privacy policy.